Patents Assigned to BAYER AS
  • Publication number: 20230117034
    Abstract: The present invention provides compounds of general formula (I), in which X, R1, R2 and R3 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of hyperproliferative disorders such as cancer disorders, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: December 9, 2020
    Publication date: April 20, 2023
    Applicants: Bayer Aktiengesellschaft, Deutsches Krebsforschungszentrum
    Inventors: Kai THEDE, Philipp BUCHGRABER, Gerhard SIEMEISTER, Patrick STEIGEMANN, Antje Margret WENGNER, Ulf BOEMER, Naomi BARAK, Philip LIENAU
  • Publication number: 20230121195
    Abstract: The present invention covers 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compounds of general formula (1): in which X, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: August 12, 2022
    Publication date: April 20, 2023
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Deutsches Krebsforschungszentrum
    Inventors: Ilona GUTCHER, Ulrike RÖHN, Norbert SCHMEES, Ludwig ZORN, Lars RÖSE, Benjamin BADER, Christina KOBER, Rafael CARRETERO, Detlef STÖCKIGT, Horst IRLBACHER, Michael PLATTEN
  • Patent number: 11630965
    Abstract: A reader system for reading information on at least one identification tag associated with a syringe connected to a fluid injector has a detector and a background screen spaced apart from the detector such that at least one of the at least one identification tags is positioned in an optical path between the detector and the background screen when the syringe is connected to the fluid injector. The reader system further has an illumination system configured for illuminating at least a portion of the background screen. The detector is configured for detecting and decoding the at least one identification tag. Methods for reading information on at least one identification tag associated with a syringe are also described.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: April 18, 2023
    Assignee: BAYER HEALTHCARE LLC
    Inventors: Christopher Capone, Jaroslaw Wlodarczyk
  • Patent number: 11628088
    Abstract: The present invention relates to ultrasonically detectable intrauterine systems and to a method for enhancing ultrasound detection of these systems. An intrauterine system having an inert metal coating on at least part of the body of the intrauterine system or at least one inert metal clip, pin, ring or sleeve fixedly positioned on the body of the intrauterine system is described.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: April 18, 2023
    Assignee: Bayer OY
    Inventors: Taina Tjäder, Sara Heinonen
  • Patent number: 11628433
    Abstract: A dispensing device includes a housing having at least one pressure chamber, having a supply opening for the supply of liquid into the pressure chamber and having a multiplicity of conduits between the pressure chamber and an external side of the housing, there being situated in each of the conduits a tube, the first end of which protrudes into the pressure chamber and the second end of which protrudes out of the housing on the external side.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: April 18, 2023
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Andreas Schade, Mike Küster, Klaus Ochmann, Michael Harnau, Karl-Hermann Koeching, Nils Burkhardt, Bernd Kalthof, Linn Schneider, Georg Schmidt
  • Publication number: 20230112499
    Abstract: The present invention covers furoindazole compounds of general formula (I): in which (I) are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of autoimmune diseases such as multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, primary and secondary autoimmune uveitis, inflammatory disorders like endometriosis, inflammatory eye diseases, inflammatory kidney diseases, inflammatory liver diseases like non-alcoholic, alcoholic- and toxic fatty liver diseases, lung diseases like asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and metabolic and metabolic-endocrine disorders like metabolic syndrome, insulin resistance, diabetes mellitus type I and type II, and po
    Type: Application
    Filed: December 14, 2020
    Publication date: April 13, 2023
    Applicant: Bayer Aktiengesellschaft
    Inventors: Olaf PANKNIN, Frank SACHER, Nicole SCHMIDT, Gernot LANGER, Katrin NOWAK-REPPEL, Reinhard NUBBEMEYER, Sabine PILARI, Antje ROTTMANN, Hideki MIYATAKE ONDOZABAL, Holger SIEBENEICHER, Antonius TER LAAK, Hana CERNECKA
  • Publication number: 20230113037
    Abstract: The present invention covers [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds of general formula (I) in which R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: August 10, 2020
    Publication date: April 13, 2023
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, DEUTSCHES KREBSFORSCHUNGSZENTRUM
    Inventors: Julien LEFRANC, Norbert SCHMEES, Ludwig ZORN, Robin Michael MEIER, Simon Anthony HERBERT, Judith GÜNTHER, Ilona GUTCHER, Lars RÖSE, Benjamin BADER, Detlef STÖCKIGT, Mátyás GORJÁNÁCZ, Christina KOBER, Bernd BUCHMANN, Stephan BÖHME, Ulrich BOTHE, Michael PLATTEN, Daniel BAUMANN
  • Publication number: 20230115270
    Abstract: The present application relates to novel substituted heterocyclic carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases and to their use for producing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of breathing difficulties including sleep-induced breathing difficulties such as central and obstructive sleep apnoea, snoring (primary and obstructive snoring), dysphagia, peripheral and cardiac vascular disorders including diabetic microangiopathies and disorders of the peripheral and central nervous system including neurodegenerative and neuroinflammatory disorders.
    Type: Application
    Filed: November 5, 2020
    Publication date: April 13, 2023
    Applicants: Bayer Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Martina DELBECK, Michael HAHN, Thomas MÜLLER, Lisa DIETZ, Magdalena PLATZK, Daniel MEIBOM, Philipp BUCHGRABER, Niels LINDNER, Eva Maria BECKER-PELSTER, Carsten SCHMECK
  • Patent number: 11623944
    Abstract: The present invention relates to a composition comprising a biologically pure culture of a fungicidal Paenibacillus sp. strain comprising a variant fusaricidin synthetase lacking a functional adenylation domain in the third module. The present invention also provides a composition comprising a biologically pure culture of a fungicidal Paenibacillus sp. strain or a cell-free extract thereof comprising at least one Paeniserine and at least one Paeniprolixin. Also provided are isolated compounds and methods of treating a plant to control a plant disease with the disclosed compositions and compounds.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: April 11, 2023
    Assignee: Bayer CropScience LP
    Inventors: Jeremy Beau, Daniel M. Joo, Patrick Schwientek, Colleen S. Taylor, Bjorn A. Traag
  • Publication number: 20230106032
    Abstract: The present invention provides compounds of general formula (I): in which X, R1, R2 and R3 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of hyperproliferative disorders such as cancer disorders, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: March 5, 2021
    Publication date: April 6, 2023
    Applicants: Bayer Aktiengesellschaft, Deutsches Krebsforschungszentrum
    Inventors: Kai THEDE, Philipp BUCHGRABER, Gerhard SIEMEISTER, Patrick STEIGEMANN, Antje Margret WENGNER, Ulf BÖMER, Naomi BARAK, Philip LIENAU
  • Patent number: 11617727
    Abstract: Provided are topical analgesic gel compositions having relatively high payloads of menthol and camphor by micro-emulsion technology and methods of preparing topical analgesic gel compositions having relatively high payloads of menthol and camphor. Topical analgesic gel compositions may include from 12 to 16 wt. % menthol; from 4 to 8 wt. % camphor; from 0.1 to 2 wt. % carbomer; and 60 to 70 wt. % solvent. Topical analgesic gel compositions can have a viscosity from 60,000 to 110,000 centipoise.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: April 4, 2023
    Assignee: Bayer Healthcare LLC
    Inventors: Debanjan Das, Emanuel Vizzotti, Thomas Dann, Renee Nelson, Courtney C. Haynes, Soundarya Vaithianathan, Reginald Bradley, Reinhard Walter, Gerard Meisel
  • Patent number: 11618735
    Abstract: The present invention relates to a novel crystal form of the monosodium salt of foramsulfuron, a method for preparing this crystal form, use thereof in agrochemical formulations and also particular compositions, mixtures or agrochemical formulations comprising this crystal form, and also a novel monomethanol solvate of the monosodium salt of foramsulfuron.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: April 4, 2023
    Assignee: Bayer CropScience Aktiengesellschaft
    Inventors: Stefan Antons, Britta Olenik, Martin Krueger
  • Patent number: 11617751
    Abstract: The present invention relates to solid pharmaceutical compositions, in particular to oral contraceptives, comprising a progestogen, such as drospirenone; an estrogen, such as ethinylestradiol; a tetrahydrofolic acid or a pharmaceutically acceptable salt thereof, such as calcium 5-methyl-(6S)-tetrahydrofolate; and at least one pharmaceutical acceptable excipient or carrier. The compositions of the invention provide good stability of the tetrahydrofolic acid upon storage while still ensuring a fast and reliable release of the estrogen and the progestogen present in the composition.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: April 4, 2023
    Assignee: BAYER PHARMA AG
    Inventor: Kristina King
  • Patent number: 11617792
    Abstract: The invention relates to pharmaceutical compositions in liquid form comprising pradofloxacin in an aqueous solution and citric acid or thioglycerol as antioxidants.
    Type: Grant
    Filed: August 20, 2020
    Date of Patent: April 4, 2023
    Assignee: Bayer Animal Health GmbH
    Inventors: Iris Heep, Patrick Billian
  • Publication number: 20230100584
    Abstract: The invention relates to the development of formulations, preferably for biologically active substances. The aim of the invention is to provide a method, a computer system, and a computer program product for predicting at least one property of at least one formulation using a prediction model which has been trained to predict formulation properties by means of a monitored learning process using reference data.
    Type: Application
    Filed: February 18, 2021
    Publication date: March 30, 2023
    Applicant: Bayer Aktiengesellschaft
    Inventors: Holger DIEDAM, Johanna ANLAHR, Heike SKÖTSCH, Matthias ERBER
  • Patent number: 11612689
    Abstract: An adapter for releasably attaching a syringe to an injector. The adapter comprises a mounting mechanism positioned at a rear end of the adapter to mount the adapter in a desired position relative to a front wall of the injector; and a syringe carrier section adapted to seat at least a portion of the syringe. The syringe carrier section defines a first opening on a top thereof to allow placement of the syringe therein from the top and a second opening in a rear section thereof to allow the drive member of the injector to communicate forward force to the plunger. A cover portion extends over a rearward end of the first opening and has a first end configured to abut the flange of the syringe when the syringe is positioned within the syringe carrier section.
    Type: Grant
    Filed: November 11, 2020
    Date of Patent: March 28, 2023
    Assignee: BAYER HEALTHCARE LLC
    Inventors: Molly Bingaman, Erin Novickoff, Patrick O'Rourke, Stephen Schulte
  • Patent number: 11613522
    Abstract: The invention relates to 3-phenylisoxazoline-5-carboxamides of tetrahydro and dihydrofuran carboxamides of general formula (I) and to their agrochemically compatible salts (I) as well as to the use thereof in the field of plant protection.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: March 28, 2023
    Assignees: Bayer Aktiengesellschaft, Bayer CropScience Aktiengesellschaft
    Inventors: Olaf Peters, Klaus Bernhard Haaf, Guido Bojack, Katherine Rose Law, Anu Bheemaiah Machettira, Hansjoerg Dietrich, Elmar Gatzweiler, Christopher Hugh Rosinger, Elisabeth Asmus
  • Patent number: 11607489
    Abstract: A fluid injection system including a graphical user interface, a fluid control module operatively connected to the graphical user interface, a monitoring control module provided in at least one of the graphical user interface and the fluid control module, a fluid injector operatively connected to the graphical user interface and the fluid control module, at least one fluid path set in fluid communication with the fluid control module, and a hemodynamic monitoring system operatively connected to the fluid path set and the monitoring control module. The hemodynamic monitoring system may be configured to receive electrical signals regarding pressure waves formed in medical fluid directed through the fluid path set based on a location of the fluid path set in a patient's vasculature, to convert the electrical signals to pressure wave form information, and to send the pressure wave form information to the monitoring control module.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: March 21, 2023
    Assignee: BAYER HEALTHCARE LLC
    Inventors: Gerald Callan, Michael Spohn
  • Publication number: 20230084899
    Abstract: The present invention relates to combinations of at least two components, component A and component B, component A being an AhR inhibitor, and component B being pembrolizumab or nivolumab. A further aspect of the present invention relates to combinations of three components, component A, component B, and component C; component A being an AhR inhibitor, component B being pembrolizumab or nivolumab, and component C being a further pharmaceutical agent. The present invention further relates to the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment or prophylaxis of cancers of the breast, respiratory tract, brain, reproductive organs, digestive tract, urinary tract, eye, liver, skin, kidney, head and neck, thyroid, parathyroid, and their distant metastases, lymphomas, sarcomas and leukemias.
    Type: Application
    Filed: December 14, 2020
    Publication date: March 16, 2023
    Applicant: Bayer Aktiengesellschaft
    Inventor: Ilona GUTCHER
  • Patent number: 11602591
    Abstract: A fluid delivery device includes: a fluid-filled cartridge comprising an outlet; a syringe comprising a substantially cylindrical syringe barrel having an open end and a fluid dispensing end; and a plunger rod configured to be received within the open end of the syringe barrel. The plunger rod comprises: a first end having a sealing member provided in sealing engagement with an inner wall of the syringe barrel such that a first syringe chamber is provided between the first end of the plunger rod and the fluid dispensing end of the syringe barrel; a second end extending out of the open end of the syringe barrel and having a cartridge-receiving chamber having a connection mechanism positioned therein for connecting the outlet of the cartridge thereto. The plunger rod also includes a fluid channel extending from the connection mechanism to the first end of the plunger rod.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: March 14, 2023
    Assignee: BAYER HEALTHCARE LLC
    Inventor: Kevin P. Cowan